Latest Breaking News On - Adverse event - Page 1 : comparemela.com

GENFIT: Historic Milestone Achieved with U S FDA Accelerated Approval of Ipsen s Iqirvo® for Primary Biliary Cholangitis | 10 06 24

GENFIT: Historic Milestone Achieved with U S FDA Accelerated Approval of Ipsen s Iqirvo® for Primary Biliary Cholangitis | 10 06 24
finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomFrance generalHong kongPascal prigentIpsen euronextIpsen iqirvoStephanie boyerExchange commissionEuropean medicines agencyDrug administrationRegulatory agencyNewborn developmentTerns pharmaceuticalsIpsen pharmaceuticalsIpsen pharmaceuticals inc

Newswire & Press Release / Ipsen s Iqirvo® Receives U S FDA Accelerated Approval as A First-in-class PPAR Treatment for Primary Biliary - Pharma / BioTech / Nutrition - IPSEN Group

Newswire & Press Release / Ipsen s Iqirvo® Receives U S FDA Accelerated Approval as A First-in-class PPAR Treatment for Primary Biliary - Pharma / BioTech / Nutrition - IPSEN Group
newswiretoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswiretoday.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongUnited kingdomFrance generalChristelle huguetIpsen iqirvoCarol robertsKris kowdleyLiver instituteEuropean medicines agencyAgency sourceIpsen pharmaceuticalsDrug administrationRegulatory agencyNewborn developmentIpsen pharmaceuticals inc

Newswire & Press Release / Ipsen s Iqirvo® Receives U S FDA Accelerated Approval as A First-in-class PPAR Treatment for Primary Biliary - Pharma / BioTech / Nutrition - IPSEN Group

Hong kongUnited statesFrance generalUnited kingdomChristelle huguetKris kowdleyCarol robertsIpsen iqirvoHead of researchIpsen pharmaceuticals incNewborn developmentRegulatory agencyLiver instituteAgency sourceIpsen pharmaceuticalsEuropean medicines agency

Ipsen s Iqirvo® receives U S FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis | Company Announcement

Ipsen s Iqirvo® receives U S FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis | Company Announcement
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

United statesFrance generalUnited kingdomHong kongIpsen euronextClin gastroenterol hepatolCarol robertsChristelle huguetAnna gibbinsIpsen iqirvoRachel reiffKris kowdleyNicolas boglerAmy wolfLiver instituteIpsen pharmaceuticals inc

Ipsen Pharma: Ipsen s Iqirvo® receives U S FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Iqirvo® (elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver

France generalUnited statesUnited kingdomHong kongChristelle huguetRachel reiffKris kowdleyNicolas boglerAnna gibbinsAmy wolfCarol robertsClin gastroenterol hepatolIpsen euronextIpsen pharmaceuticals incRegulatory agencyLiver institute